


Prostate Cancer Research Review™



Making Education Easy

Issue 77 - 2024

In this issue:

- > ⁶⁸Ga-RM2 PET-MRI for evaluation of prostate cancer
- > ADT intensification in biochemically relapsed CSPC
- > Pelvic irradiation for node-positive prostate cancer after prostatectomy
- > Association of BMI with tumour aggression
- > Focal therapy with high-intensity focused ultrasound
- > ADT and prostate cancer outcomes according to competing event risk
- > Neoadjuvant chemohormonal therapy vs hormonal therapy
- > Intermittent vs continuous ADT in CSPC
- > Risk factors for prostate cancer
- > Phase I study of acapatamab for mCRPC

Abbreviations used in this issue:

ADT = androgen-deprivation therapy; BMI = body mass index;
CRPC = castration-resistant prostate cancer;
CSPC = castration-sensitive prostate cancer; DRE = digital rectal exam;
EBRT = external beam radiotherapy; GG = grade group; IL = interleukin;
ISUP = International Society of Urological Pathology;
mCRPC = metastatic castration-resistant prostate cancer;
MRI = magnetic resonance imaging; OR = odds ratio; OS = overall survival;
PET = positron emission tomography; PFS = progression-free survival;
PSMA = prostate-specific membrane antigen; RR = relative risk.



RESEARCH REVIEW™

Australia's Leader in Specialist Publications

Welcome to Issue 77 of Prostate Cancer Research Review.

In a phase 2/3 imaging trial, ⁶⁸Ga-RM2 PET-MRI showed better diagnostic performance than MRI alone in patients with biochemical recurrence of prostate cancer. In the PRESTO study, intensified androgen receptor blockade with apalutamide prolonged progression-free survival without impacting testosterone recovery in men with biochemically recurrent prostate cancer. We conclude this issue with a first-in-human study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer.

I hope you find the research in this issue useful to you in your practice and I look forward to your comments and feedback.

Kind Regards,

Professor Niall Corcoran

niall.corcoran@researchreview.com.au

⁶⁸Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: A single-centre, single-arm, phase II/III imaging trial

Authors: Duan H et al.

Summary: This single-centre, single-arm, phase II/III trial assessed the diagnostic performance of a gastrin-releasing peptide receptors (GRPR)-targeting tracer ⁶⁸Ga-RM2 in PET-MRI in 100 men with prostate cancer biochemical recurrence. Over a median follow-up of 49.3 months, ⁶⁸Ga-RM2 PET-MRI was positive in 69% of patients versus 20% positive by MRI alone ($p < 0.0001$). In per-lesion analysis ⁶⁸Ga-RM2 PET-MRI had higher detection rates than MRI alone (143 vs 96 lesions; $p < 0.0001$).

Comment: Up to 10% of prostate tumours do not express PSMA, so there is increasing interest in identifying other potential markers that may be targeted for imaging or therapy. One of these is GRPR, which is aberrantly overexpressed on the cell surface of prostate cancer. This single-arm study compared the rates of disease detection by PET-MRI using a radiolabelled GRPR ligand compared to MRI alone in patients with biochemical recurrence post-surgery or radiation and negative conventional imaging. Compared with whole body MRI with contrast enhanced delayed imaging of the pelvis, ⁶⁸Ga-RM2 PET-MRI was more sensitive for disease detection, largely driven by better detection of local recurrence and lymph node metastases. Interesting findings, but we really need a head-to-head comparison with PSMA targeted imaging to clarify incremental benefit.

Reference: *Lancet Oncol.* 2024;25(4):501-508

[Abstract](#)




Prostate Cancer Research Review™

Independent commentary by Professor Niall Corcoran.

Professor Niall Corcoran is a urological surgeon and translational scientist based in Melbourne. He is Head of the Urology Unit at Western Health and a visiting surgeon at Royal Melbourne and Frankston Hospitals. His group in the University of Melbourne Centre for Cancer Research investigates molecular drivers of prostate cancer metastases and treatment resistance.

Earn CPD

Nursing and Midwifery Board of Australia (NMBA) Journal reading and watching videos (including Research Reviews) may be considered a self-directed activity set out in the [NMBA Registration Standard: Continuing Professional Development](#). One hour of active learning will equal one hour of CPD. Details at [NMBA CPD page](#).



PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)

Authors: Aggarwal R et al.

Summary: This randomised, open-label, phase III trial evaluated whether ADT intensification improved outcomes in 503 patients with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy comparing ADT control, ADT plus apalutamide, or ADT plus apalutamide plus abiraterone acetate plus prednisone (AAP). At a first interim analysis, compared with controls, PSA progression-free survival (PSA-PFS; serum PSA >0.2 ng/mL) was prolonged in ADT plus apalutamide recipients (median 24.9 vs 20.3 months; HR 0.52; 95% CI 0.35-0.77; $p = 0.00047$) and ADT plus apalutamide plus AAP recipients (median 26.0 vs 20.0 months; HR 0.48; 95% CI 0.32-0.71; $p = 0.00008$). Median time to testosterone recovery did not differ between treatments. Hypertension was the most common grade ≥ 3 adverse event in ADT, ADT plus apalutamide, and ADT plus apalutamide plus AAP recipients (7.5% vs 7.4% vs 18%).

Comment: The EMBARK study previously showed that treatment intensification of men with high-risk biochemical recurrence (PSA doubling time <9 months) with a combination of ADT plus enzalutamide following radical prostatectomy +/- salvage radiation improved metastasis-free survival (MFS) compared to ADT alone. This similar study reports on the impact of 52 weeks of ADT plus apalutamide or ADT plus apalutamide plus abiraterone on PSA-PFS compared to ADT alone in essentially the same clinical population. Treatment intensification delayed time to PSA progression (the primary study endpoint) in both groups compared to ADT, which is not unexpected considering the previous findings. However, the additional benefit of using two novel hormonal agents was incremental and offset somewhat by an increased grade 3/4 toxicity. Data on more impactful outcomes such as MFS are awaited.

Reference: *J Clin Oncol.* 2024;42(10):1114-1123

[Abstract](#)

Pelvic irradiation for node-positive prostate cancer after prostatectomy: Long-term results of the prospective PLATIN-4 and PLATIN-5 trials

Authors: Fink CA et al.

Summary: These two small phase II trials assessed the use of salvage radiation therapy (RT) to the pelvic lymph nodes in 78 patients with node-positive prostate cancer after radical prostatectomy (PLATIN-4 trial) or after radical prostatectomy and prostate bed radiation therapy (PLATIN-5 trial), who received salvage pelvic lymph node RT with boost to involved nodes as field abutment (PLATIN-5) or boost to the prostate bed (PLATIN-4). ADT was commenced 2 months before radiation and continued for 24 months. Median OS was not reached in PLATIN-4 and 117 months in PLATIN-5, and median PFS was 66 months and 39 months. Late grade >3 genitourinary and gastrointestinal toxicities occurred in 4% of patients at 24 months.

Comment: There is a paucity of long-term prospective data on the utility of pelvic side wall irradiation in patients with residual/recurrent nodal disease following radical prostatectomy with a lymph node dissection. This German report synthesises data from two prospective phase II studies which investigated the efficacy of pelvic nodal basin irradiation (including a boost to positive nodes on conventional imaging or PSMA-PET) in combination with 2 years of ADT for lymph node recurrence after prostatectomy, with or without previous adjuvant/salvage prostate bed irradiation. Although the populations of both trials differed in terms of their risk of undetected systemic disease, a significant proportion remained disease free after irradiation in both cohorts suggesting it can produce long-term disease control in selected patients. The strongest predictor of failure in both groups was involvement of common iliac nodes.

Reference: *Int J Radiat Oncol Biol Phys.* 2024;118(4):1011-1017

[Abstract](#)

The association of body mass index with tumor aggression among men undergoing radical prostatectomy

Authors: Gregg JR et al.

Summary: This study examined the association of preoperative BMI with adverse pathology in peripheral and transition zone tumours in 923 patients undergoing prostatectomy for localised prostate cancer. Overall, 15% of patients had "normal" BMI (18.5-24.9 kg/m²), 45% were "overweight" (25-29.9 kg/m²), and 40% were "obese" (>29.9 kg/m²) while 51% of patients had aggressive peripheral zone tumours and 11% had aggressive transition zone tumours. An "obese" BMI was not associated with aggressive transition zone tumours compared to a "normal" weight; however, increasing BMI was associated with an increased risk of aggressive peripheral zone tumours (HR 1.56; 95% CI 1.04-2.34; $p = 0.03$). In patients with grade group (GG) 1 or GG2 tumours, increasing BMI was associated with pT3a or greater transition zone tumours ($p = 0.03$).

Comment: The association of increased BMI with more aggressive prostate cancer is well documented, attributed both to underestimation of disease risk in obese men (low relative PSA levels due to haemodilution; DRE less sensitive) as well as an increase in molecular drivers of progression (for instance, IL-6). This observation is further supported by this case series from MD Anderson, where increasing BMI category was associated with an increased risk of aggressive disease, defined as either ISUP GG >3 or pT >3a. The more interesting observation is the distribution of BMIs in patients undergoing RARP at this centre – only 15% were normal weight, and 40% were obese or higher. Testing times in Texas.

Reference: *Urol Oncol.* 2024;42(4):116.e1-116.e7

[Abstract](#)

Focal therapy with high-intensity focused ultrasound for prostate cancer: 3-year outcomes from a prospective trial

Authors: Kaufmann B et al.

Summary: This 3-year, multicentre, prospective study used periodic post-ablation saturation biopsies to assess outcomes of focal high-intensity focused ultrasound (HIFU) in 91 patients with localised prostate cancer (6 with GG1 and 85 GG ≥ 2). Overall, 83 (91%) patients received at least one follow-up biopsy, with biopsy attendance rates at 6, 12, and 36 months of 84%, 67%, and 51%. Failure-free survival (FFS) rates at 6, 12, and 36 months for any GG ≥ 2 prostate cancer were 79% (95% CI 80-88), 57% (95% CI 48-69) and 44% (95% CI 34-56%). Using a second definition of FFS (GG ≥ 3 or core involvement of ≥ 6 mm) rates were 88% (95% CI 81-95), 70% (95% CI 61-81) and 65% (95% CI 55-77); 3-year cancer-specific survival was 100%, and freedom from metastasis was 99%. MRI and relative decrease of PSA values were poor at detecting residual disease. Overall, 17 (21%) patients reported worsening erectile function.

Comment: A consistent criticism of data in support of focal therapy is that most of the outcomes reported are based on short-term follow-up in patients with reasonably indolent disease. Addressing, at least in part, the latter, the authors report on 3-year outcomes for patients with low/intermediate risk disease (67% ISUP GG2; 24% ISUP GG3) treated with HIFU (up to 2 lesions) in a multicentre prospective study. As expected, reported functional outcomes were excellent, with little change to baseline urinary or sexual function. However less than half of patients remained free of ISUP GG2 disease at 3 years, with almost 20% progressing to whole gland or systemic therapy. An additional concern is that MRI post HIFU has poor test performance for detecting recurrent disease. Caveat emptor.


Reference: *BJU Int.* 2024;133(4):413-424

[Abstract](#)

Follow us at:



RESEARCH REVIEW™ Australia's Leader in Specialist Publications



PBS LISTED¹

✓ mHSPC
✓ nmCRPC

CONFIDENCE WITHOUT Compromise^{2-5*}

*Extend patients' lives without compromising quality of life

In mHSPC: NUBEQA® + ADT + docetaxel reduced the relative risk of death by 32.5% vs ADT + docetaxel (HR 0.68, 95% CI 0.57-0.80; P<0.001 [primary endpoint]); frequency of AEs and discontinuations were comparable to ADT + docetaxel alone.^{2,3}

In nmCRPC: NUBEQA® + ADT significantly improved OS vs ADT alone (HR 0.69, 95% CI 0.53-0.88; P=0.003 [secondary endpoint]); significantly improved MFS vs ADT alone (40.4 vs 18.4 months; HR 0.41, 95% CI 0.34-0.50; P<0.001 [primary endpoint]). Patient QOL was maintained throughout the duration of treatment; frequency of AEs and discontinuations were comparable to ADT alone.^{2,4,5}

NUBEQA® is indicated for the treatment of patients with mHSPC (in combination with docetaxel) and nmCRPC.²

ADT, androgen deprivation therapy; AE, adverse event; CI, confidence interval; HR, hazard ratio; MFS, metastasis-free survival; mHSPC, metastatic hormone-sensitive prostate cancer; nmCRPC, non-metastatic castration resistant prostate cancer; OS, overall survival; PBS, Pharmaceutical Benefits Scheme; QOL, quality of life.



NUBEQA®
(darolutamide) 300 mg tablets

PBS Information: This product is listed on the PBS for non-metastatic castration resistant prostate cancer and metastatic hormone-sensitive prostate cancer. Refer to PBS schedule for more information www.pbs.gov.au



Please review Product Information before prescribing. Full Product Information available upon request from Bayer Australia Ltd or by scanning the QR code.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.


MINIMUM PRODUCT INFORMATION NUBEQA® (darolutamide)

INDICATIONS: NUBEQA is indicated for the treatment of patients with non-metastatic castration resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel. **CONTRAINDICATIONS:** Hypersensitivity to darolutamide or excipients in tablet, women who are or may become pregnant. **PRECAUTIONS:** Cardiovascular events (the safety of darolutamide has not been characterised in patients with recent (within 6 months) cardiovascular events), hepatic impairment, renal impairment. The safety and efficacy in children and adolescents (< 18 years) have not been established. Ischemic heart disease, including fatal cases, occurred in patients receiving NUBEQA. Patients should be monitored for signs and symptoms of ischemic heart disease. Optimise management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidaemia. Seizure occurred in patients receiving NUBEQA. Cases of idiosyncratic drug induced liver injury (DILI) consisting of Grade ≥ 3 increases in ALT and/or AST, including with concomitant bilirubin $\geq 2x$ ULN, have been reported with NUBEQA. In case of liver function test abnormalities suggestive of idiosyncratic DILI, permanently discontinue NUBEQA. **INTERACTIONS WITH OTHER MEDICINES:** Darolutamide is a substrate of CYP3A4, P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). Darolutamide is an inhibitor of BCRP and Organic Anion Transporting Polypeptides (OATP) 1B1 and 1B3 and a weak inducer of CYP3A4. In vitro data indicate darolutamide administration may inhibit OAT3, MATE1, MATE2K and intestinal MRP2. Darolutamide did not inhibit the transporters, BSEP, OAT1, OCTs, OATP2B1 and Ntcp at clinically relevant concentrations. Please refer to the full Product Information for more information. **ADVERSE EFFECTS:** The most frequently observed adverse drug reaction ($\geq 10\%$, very common) in patients with nmCRPC receiving NUBEQA is fatigue. The most frequently observed adverse drug reaction ($>10\%$) in patients with mHSPC receiving NUBEQA in combination with docetaxel were constipation (23%), decreased appetite (19%), rash (19%) and hypertension (14%). Drug-induced liver injury with increases in ALT and AST has been reported in patients treated with NUBEQA in clinical trials. **Laboratory test abnormalities** include neutrophil count decrease, bilirubin increase and AST increase in nmCRPC patients. Laboratory test abnormalities include anaemia, white blood cell and neutrophil count decrease, ALT and AST increase, hyperglycaemia and hypocalcaemia in patients with mHSPC. Cases of idiosyncratic drug-induced liver injury with increases in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) to $\geq 5x$ and $\geq 20x$ upper limit of normal (ULN), including with concomitant bilirubin elevation $\geq 2x$ ULN, have been reported in patients treated with NUBEQA. Please refer to full Prescribing Information for a complete list of adverse effects and laboratory test abnormalities. **DOSAGE AND ADMINISTRATION:** 600 mg (two film-coated tablets of 300 mg) taken twice daily, equivalent to a total daily dose of 1200 mg. The tablets should be taken whole with food. Patients receiving NUBEQA should also receive a gonadotropin-releasing hormone (GnRH) analogue concurrently or should have had bilateral orchiectomy. In case of toxicity or an intolerable adverse reaction, dosing should be withheld or reduced. For more information see full Prescribing Information. **DATE OF PREPARATION:** August 2023, based on PI dated 23-August-2023.

References: 1. Pharmaceutical Benefits Scheme. www.pbs.gov.au. 2. NUBEQA® (darolutamide) Approved Product Information. 3. Smith MR et al. N Engl J Med 2022;386(12):1132-1142. 4. Fizazi K et al. N Engl J Med 2019;380(13):1235-1246 (including Supplementary Appendix). 5. Fizazi K et al. N Engl J Med 2020;383(11):1040-1049.

NUBEQA® is a registered trademark of Bayer Group, Germany, Bayer Australia Limited. ABN 22 000 138 714. 875 Pacific Highway, Pymble NSW 2073. NUB194 | January 2024 | PP-NUB-AU-0273-2





Effects of androgen deprivation therapy on prostate cancer outcomes according to competing event risk: Secondary analysis of a phase 3 randomised trial

Authors: Mell LK et al.

Summary: This ancillary analysis of a phase III trial in 1945 prostate cancer patients assessed whether a quantitative stratification method using risk for competing events (omega score) could identify subgroups that benefit from ADT. Relative risk (RR) for cancer-related versus competing mortality events (a higher omega score) was increased by T category (T2b), higher Gleason score, and higher PSA and decreased by increased age and comorbidity. Among 996 patients with low-risk/favourable intermediate-risk disease, 28.7% had a high omega score (≥ 0.314), while among 768 patients with unfavourable intermediate-risk disease 22.8% had a low omega score. Overall risk classification discordance was 26.1%. There were significant interactions for the effect of ADT on cancer-related events and late mortality across low- versus high-risk subgroups. Within the low-/favourable risk subgroup, a higher omega score identified patients where ADT reduced cancer events and improved event-free survival.

Comment: ADT improves the efficacy of external beam radiotherapy but comes at a cost of physiological changes that may increase the risk of death from other causes. This competing risk analysis examined data from a large, randomised control trial which showed that short course ADT improved oncological outcomes in men with low/intermediate risk disease treated with EBRT, to identify factors that select patients most likely to benefit (cancer benefits > deleterious effect on non-cancer mortality). The results are somewhat intuitive, patients with higher grade and stage disease were more likely to benefit, whereas older patients with increasing co-morbidities were less likely to benefit. Interestingly, almost 30% of patients with low/favourable intermediate risk prostate cancer were found to benefit from short course ADT, highlighting again the vagaries of trying to force continuous risk into a small number of categories.

Reference: *Eur Urol.* 2024;85(4):373-381

[Abstract](#)

A prospective randomized trial of neoadjuvant chemohormonal therapy vs hormonal therapy in locally advanced prostate cancer treated by radical prostatectomy

Authors: Qian H et al.

Summary: This randomised controlled trial examined whether docetaxel-based neoadjuvant chemohormonal therapy (NCHT) could improve biochemical PFS versus neoadjuvant hormonal therapy (NHT) in 141 patients with locally advanced prostate cancer. NCHT recipients experienced benefits in 3-year biochemical PFS versus NHT recipients (29% vs 9.5%; $p = 0.002$). After a median 53-month follow-up, NCHT recipients had a longer median biochemical PFS than NHT recipients (17 vs 14 months). There were no differences in pathological downstaging and minimal residual disease rates.

Comment: Although neo-adjuvant trials based on novel hormonal agents have shown some promising long-term results in patients achieving good pathological responses, results using neo-adjuvant chemotherapy have been generally disappointing (for instance the CALGB Alliance trial). In contrast, this randomised phase II study from China shows a significant but modest improvement in biochemical recurrence with neoadjuvant docetaxel/ADT compared to ADT alone. One clear difference is the much higher risk profile of this cohort (median PSA >90 ng/mL; ~50% cN1), suggesting the majority of patients had unmeasured metastatic disease at diagnosis. Still longer-term follow-up is needed to see if there is any meaningful effect on metastasis-free survival.

Reference: *J Urol.* 2024;211(5):648-655

[Abstract](#)

Intermittent versus continuous androgen deprivation therapy for biochemical progression after primary therapy in hormone-sensitive nonmetastatic prostate cancer: Comparative analysis in terms of CRPC-M0 progression

Authors: Salciccia S et al.

Summary: This retrospective study examined use of intermittent versus continuous ADT in 170 patients with biochemical progression after primary treatment in prostate cancer and the effect on development of nonmetastatic CRPC. There was no difference in CRPC progression between intermittent (25.8%) and continuous (30.5%) treatment after a mean of 32.7 and 35.6 months. Mean PSA at CRPC development was higher in intermittent ADT recipients (5.16 vs 3.1 ng/mL; $p < 0.001$). Univariate analysis suggested that continuous ADT administration increases the risk for CRPC progression (RR 3.48; 95% CI 1.66-7.29; $p = 0.01$) compared to intermittent administration; multivariate analysis confirmed an effect independent of other variables (RR 2.34; 95% CI 1.52-5.33; $p = 0.03$).

Comment: Intermittent ADT is a common strategy for men with biochemical progression after failed local treatment +/- salvage therapy based on decade old phase III data demonstrating non-inferior oncological outcomes (OS, disease specific survival and 'corrected' time to castration resistance) compared to continuous ADT post radiotherapy. These data are challenged by this small retrospective study which finds that continuous ADT was associated with a shorter time to non-metastatic CRPC but not metastatic CRPC compared to intermittent therapy. As well as having many methodological issues (particularly small numbers and high rates of missing data), the authors fail to 'correct' for the inherent delay in making a diagnosis of castration resistance in patients on intermittent ADT. So not particularly useful, except for confirming that in the real-world setting there is little difference between the two strategies, except perhaps the cost to the healthcare system.

Reference: *Clin Genitourin Cancer* 2024;22(2):74-83

[Abstract](#)

Earn CPD

Royal Australasian College of Physicians (RACP) MyCPD participants can claim the time spent reading and evaluating research reviews as CPD in the online [MyCPD program](#). Please contact MyCPD@racp.edu.au for any assistance.

Royal Australian & New Zealand College of Radiologists (RANZCR) members can claim reading related to their practice as a CPD activity under the category 'journal reading and web based no certificate *reflection required'. [More info.](#)


Kindly Supported by

Australian Prostate Centre 

ANZUP
Cancer Trials Group Limited 

REGISTRATIONS AND ABSTRACTS NOW OPEN!
ANZUP ANNUAL SCIENTIFIC MEETING 21-23 JULY 2024
GOLD COAST CONVENTION & EXHIBITION CENTRE • 'MAKING WAVES'





Risk factors for prostate cancer: An umbrella review of prospective observational studies and mendelian randomization analyses

Authors: Cui H et al.

Summary: This umbrella review sought to identify factors modifying the risk of prostate cancer reported in 92 meta-analyses of prospective observational studies and 64 Mendelian randomisation (MR) analyses. Overall, 45 significant observational associations and 55 significant causal associations were categorised into lifestyle; diet and nutrition; anthropometric; biomarkers; clinical variables, diseases and treatments; and environmental factors. Meta-analyses identified five highly suggestive, 36 suggestive, and four weak associations, and Mendelian randomisation studies identified 10 robust, 24 probable, four suggestive, and 17 insufficient causal associations. There were 26 overlapping factors between meta-analyses and MR studies identified, with consistent effects for physical activity in meta-analyses (OR 0.87; 95% CI 0.80-0.94) and Mendelian analyses (OR 0.49; 95% CI 0.33, 0.72), height (OR 1.09; 95% CI 1.06-1.12; OR 1.07; 95% CI 1.01-1.15 for aggressive prostate cancer), and current smoking (OR 0.74; 95% CI 0.68-0.80) or smoking initiation (OR 0.91; 95% CI 0.86-0.97).

Comment: The strongest risk factors for prostate cancer (age, family history etc.) are generally unalterable. However, in the face of rising prostate cancer incidence globally with increasing life expectancy, identification of weak but modifiable risk factors could play a major role in disease prevention. This study synthesised data from multiple meta-analyses of prospective observational studies and Mendelian randomised studies to identify robust and consistent modifiable risk factors associated with prostate diagnosis. Only 3 factors showed consistent associations with prostate cancer across the analysis, including physical activity and smoking, which were both associated with a decreased incidence (the latter possibly related to decreased testing), as well as height, which was associated with an increased incidence. Associations were reasonably weak, and apart from a recommendation to maintain physical activity throughout life, hard to implement clinically.

Reference: *PLoS Med.* 2024;21(3):e1004362

[Abstract](#)

A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer

Authors: Dorff T et al.

Summary: In this first-in-human study, the safety and efficacy of acapatamab, a PSMA x CD3 bispecific T-cell engager (BiTE) were evaluated in patients with mCRPC refractory to androgen receptor pathway inhibitor therapy and taxane-based chemotherapy. Patients received IV acapatamab 0.003 to 0.9 mg in dose exploration (7 dose levels; n = 77) or 0.3 mg (recommended phase II dose; n = 56) in dose expansion every 2 weeks. The most common treatment-emergent adverse event was cytokine release syndrome (CRS), observed in 97.4% of patients in the dose exploration group and 98.2% of patients in the dose expansion group, with grade ≥ 3 CRS observed in 23.4% and 16.1%, respectively. Antidrug antibodies were seen in 55% of patients and impacted serum exposures in 36% of patients in the dose expansion group. The incidence and severity of CRS reduced after cycle one. PSA50 responses (PSA decrease of $>50\%$ compared to baseline) were observed in 30.4% of the dose expansion group and radiographic partial responses were observed in 7.4% (Response Evaluation Criteria in Solid Tumors 1.1). The median radiographic PFS (Prostate Cancer Clinical Trials Working Group 3) was 3.7 months (95% CI 2.0-5.4) and the PSA PFS was 3.3 months (95% CI 3.0-4.9). Induction of T-cell activation and a several-fold increase in cytokine production was observed within 24 hours of starting acapatamab.

Comment: BiTEs are agents that recruit endogenous anti-tumour T cells to cancer cells independent of the major histocompatibility complex leading to tumour cell kill. This phase I study led by Ben Tran from Melbourne, investigated the safety and efficacy of a CD3 specific BiTE targeting PSMA in patients with mCRPC. In the dose expansion cohort, PSA responses were seen in 30% of patients, although radiological responses were infrequent and of limited duration. Cytokine release syndrome was almost universal, although was usually mild. Although probably not relevant for this agent, I can't help thinking that the best clinical setting for immunotherapy (and potentially long-term disease control) is in patients with minimal residual disease (PSA persistence or rapid biochemical recurrence) after prostatectomy.

Reference: *Clin Cancer Res.* 2024;30(8):1488-1500

[Abstract](#)

Research Review has you covered 50+ clinical areas

Update your subscription at
www.researchreview.com.au

Login to your profile and update your subscriptions. Trouble logging in – Email Us



RESEARCH REVIEW

Australia's Leader in Specialist Publications



Australian Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

Research Reviews are prepared with an independent commentary from relevant specialists. To become a reviewer please email geoff@researchreview.com.au.

Research Review Australia Pty Ltd is an independent Australian publisher. Research Review receives funding from a variety of sources including Government depts., health product companies, insurers and other organisations with an interest in health. Journal content is created independently of sponsor companies with assistance from leading local specialists. **Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time. **Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.

Research Review publications are intended for Australian health professionals.

